Jason C. Mixdorf

This study engineers single-domain antibodies to improve targeting of FAP, showing that valency and molecular weight affect tumor uptake and biodistribution.

This paper develops a shark-derived VNAR-based theranostic agent for MET-altered NSCLC, showing imaging and therapeutic efficacy in preclinical models.

The paper develops FAP-targeted theranostics using VNARs from a shark antibody library, showing high affinity and efficacy in vitro and in vivo.